Efficacy of cefiderocol and levofloxacin against Stenotrophomonas maltophilia in a hemorrhagic pneumonia mouse model
Abstract
ABSTRACT Cefiderocol (CFDC) is a promising drug for treating infections caused by Stenotrophomonas maltophilia , a multidrug-resistant pathogen. However, no evidence of its efficacy against S. maltophilia -induced hemorrhagic pneumonia has been reported. We compared the effects of CFDC and levofloxacin (LVFX) on improving survival as well as reducing bacterial load and pathological effects in a mouse model of S. maltophilia hemorrhagic pneumonia. The dosage of LVFX and CFDC was determined using a previously described method to establish S. maltophilia- induced hemorrhagic pneumonia in mice. CFDC and LVFX were administered intraperitoneally 3 h after bacterial infection. Treatment was administered using the calculated dosages. CFDC significantly improved survival, showed a tendency to reduce bacterial load in the blood and lungs, and revealed that hemorrhage was suppressed in pathological analysis compared with the control group. These results support the current recommendation for CFDC as a treatment option for S. maltophilia infections. However, its efficacy in our model was lower than that of LVFX. This may be due to the superior pulmonary tissue penetration of LVFX. Treatment strategies that consider tissue penetration are necessary for severe S. maltophilia infections. However, the use of LVFX must consider the risk of resistance development, whereas CFDC may be advantageous for treating resistant pathogens.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.